sinc
interferon
ifn
type
ifn
identifi
mani
anim
canin
mice
demonstr
antivir
antiprolifer
antitumor
activ
similar
date
explor
treatment
option
diseas
viral
infect
human
anim
studi
reveal
human
display
antitumor
activ
model
human
cancer
cell
use
diagnos
diseas
recombin
felin
licens
sever
countri
treat
canin
parvoviru
felin
leukemia
viru
felin
immunodefici
viru
infect
also
exhibit
certain
efficaci
use
treat
viral
infect
diseas
review
examin
known
biolog
activ
clinic
applic
expect
inform
provid
review
stimul
studi
therapeut
agent
interferon
ifn
first
report
isaac
lindenmann
antivir
protein
gener
cell
respons
viral
infect
ifn
compos
three
subgroup
type
type
ii
type
iii
ifn
type
ifn
includ
exert
biolog
activ
common
receptor
receptor
type
ii
ifn
name
produc
lymphocyt
natur
killer
cell
respons
recognit
infect
cell
type
iii
ifn
consist
regul
immun
respons
via
distinct
receptor
complex
use
signal
pathway
similar
type
ifn
gene
first
found
human
diverg
gene
approxim
million
year
ago
produc
primarili
leukocyt
human
gene
includ
four
pseudogen
one
full
gene
express
leukocyt
human
share
amino
acid
sequenc
homolog
similar
function
amino
acid
similar
similar
ifn
also
produc
cell
respons
viral
infect
biolog
activ
bind
receptor
activ
pathway
similar
activ
ifnar
activ
protein
kinas
b
signal
also
vital
biolog
respons
mediat
howev
antigen
structur
distantli
relat
crossreact
antibodi
result
treatment
effect
patient
resist
although
studi
extens
knowledg
still
limit
compar
interferon
provid
broad
review
known
biolog
activ
potenti
clinic
applic
overal
hope
inform
provid
review
stimul
studi
therapeut
agent
identifi
human
felin
pig
hors
rabbit
serotin
bat
cattl
sheep
found
canin
mice
howev
characterist
differ
differ
speci
characterist
differ
speci
summar
tabl
despit
differ
common
characterist
exist
speci
gener
gene
intronless
nglycosyl
site
present
felin
transcript
factor
bind
site
irf
isr
present
promot
region
gene
addit
mammalian
gene
lack
prolin
codon
preced
final
conserv
cystein
codon
protein
contain
sever
conserv
residu
arginin
posit
cystein
residu
posit
seven
prolin
four
locat
posit
matur
protein
posit
form
two
disulfid
bond
residu
present
similar
locat
type
ifn
vital
biolog
activ
conserv
structur
motif
region
amino
acid
residu
highli
conserv
among
protein
play
key
role
biolog
activ
addit
structur
similar
type
ifn
also
display
physicochem
characterist
type
ifn
high
sensit
trypsin
insensit
temperatur
stabil
ph
studi
reveal
lose
antivir
activ
treat
trypsin
howev
retain
high
antivir
activ
vesicular
stomat
viru
exposur
ph
h
temperatur
rang
base
analys
phylogenet
tree
obtain
align
protein
sequenc
mammal
speci
propos
protein
evolv
common
ancestor
type
ifn
includ
display
common
mechan
action
ifn
interact
specif
cellsurfac
receptor
express
ifnstimul
gene
isg
induc
encod
antivir
effector
molecul
signal
protein
transcript
factor
apoptot
protein
chemokin
regul
ifn
signal
host
respons
posit
neg
manner
except
propos
share
antivir
activ
bind
type
ifn
receptor
complex
studi
reveal
induc
transcript
gene
howev
differ
show
certain
degre
crossspeci
activ
therefor
ifn
could
exhibit
differ
physiolog
function
host
exampl
bovin
protect
madindarbi
bovin
kidney
cell
primari
embryo
bovin
lung
tabl
differ
speci
characterist
gene
protein
locat
characterist
gene
protein
refer
human
human
chromosom
human
least
five
member
one
member
human
famili
function
gene
result
function
glycosyl
protein
protein
six
addit
amino
acid
locat
carboxylterminu
amino
acid
residu
singl
polypeptid
chain
compris
two
disulfid
bond
nglycosylationlink
site
amino
acid
term
primari
structur
type
ifn
approxim
amino
acid
sequenc
ident
cat
data
felin
includ
subtyp
contain
aminotermin
secretori
signal
sequenc
residu
matur
sequenc
contain
four
highli
conserv
cystein
posit
seven
prolin
four
posit
matur
protein
protein
six
addit
amino
acid
carboxylterminu
compar
among
subtyp
contain
sevenaminoacid
insert
posit
insert
locat
compar
higher
antivir
activ
subtyp
interestingli
differ
mammalian
subtyp
subtyp
nglycosyl
recognit
site
pig
chromosom
porcin
contain
seven
eight
member
variabl
open
read
frame
length
extens
similar
sequenc
bovin
leukocyt
lowest
one
equin
contain
ifabd
function
domain
multipl
put
bind
site
type
ifn
receptor
subunit
one
put
nglycosyl
site
asnaspxserthr
subtyp
protein
five
alphahelic
bear
aminotermin
signal
peptid
four
conserv
cystein
residu
also
found
addit
subtyp
except
whose
carboxylterminu
residu
shorter
subtyp
extend
residu
pair
share
ident
sequenc
hors
chromosom
hors
contain
eight
member
plu
four
pseudogen
greater
number
gene
divers
type
ifn
gene
gene
contain
put
glycosyl
sequenc
asnthrthr
posit
protein
six
alphahelic
contain
ifabd
interferon
ifabd
domain
multipl
put
bind
site
type
ifn
receptor
subunit
nglycosyl
site
notabl
length
open
read
frame
subtyp
invari
rabbit
data
rabbit
famili
compris
least
eight
gene
display
highest
degre
homolog
human
lowest
murin
two
bind
site
nucleotid
posit
hexam
repeat
sequenc
noncod
sequenc
repetit
motif
similar
mani
downstream
region
gene
encod
inflammatori
cytokin
addit
immedi
promot
region
rabbit
gene
high
proport
purin
residu
atg
sequenc
found
promot
region
nucleotid
posit
similarli
includ
four
cy
residu
amino
acid
posit
cattl
chromosom
famili
cattl
consist
member
contain
two
pseudogen
function
gene
among
subtyp
nucleotid
similar
amino
acid
ident
subtyp
encod
amino
acid
expect
lack
nine
amino
acid
residu
carboxyl
terminu
addit
cell
felin
kidney
cell
porcin
kidney
cell
rabbit
kidney
cell
primari
bovin
testicular
cell
vesicular
stomat
viru
challeng
howev
antivir
activ
low
madindarbi
bovin
kidney
cell
high
porcin
kidney
bovin
testicular
cell
addit
protect
effect
found
madindarbi
bovin
kidney
cell
babi
hamster
kidney
cell
result
suggest
cell
tendenc
insensit
distantli
relat
speci
antivir
activ
also
vari
subtyp
viral
strain
use
challeng
previou
studi
express
upregul
fewer
residu
carboxyl
terminu
subtyp
detect
porcin
kidney
cell
challeng
pseudorabi
viru
poli
poli
c
interestingli
level
also
increas
peripher
blood
mononuclear
cell
challeng
pseudorabi
viru
upregul
studi
similarli
recombin
serotin
bat
inhibit
european
bat
lyssaviru
type
european
bat
lyssaviru
type
rabi
viru
replic
dosedepend
manner
differ
biolog
activ
elicit
order
european
bat
lyssaviru
type
rabi
viru
european
bat
lyssaviru
type
antivir
activ
also
compar
ifn
cell
respect
treat
type
type
iii
ifn
cell
treat
concentr
ngml
obvious
repress
replic
influenza
viru
dosedepend
manner
result
larger
reduct
viral
titer
compar
obtain
howev
activ
much
lower
activ
slightli
lower
activ
depend
dose
pretreat
cell
human
significantli
reduc
load
influenza
viru
interestingli
show
similar
inhibitori
activ
influenza
virus
everi
concentr
test
addit
significantli
potent
far
inhibitori
effect
stain
given
concentr
addit
vitro
activ
demonstr
antivir
activ
vivo
well
exampl
robust
induct
mx
mrna
protein
found
anim
treat
compar
control
furthermor
follow
daili
intraven
treatment
human
viral
load
influenza
viru
decreas
significantli
lung
tissu
guinea
pig
exhibit
ident
inhibitori
effect
influenza
viru
compar
although
demonstr
promis
antivir
activ
viral
infect
vivo
vitro
sever
factor
could
limit
antivir
efficaci
poor
pharmacokinet
short
halflif
pegyl
coval
conjug
nontox
polyethylen
glycol
peg
demonstr
improv
plasma
halflif
therapeut
protein
decreas
proteolyt
sensit
recent
yu
et
al
found
pegyl
improv
poor
pharmacokinet
recombin
despit
fact
antivir
activ
decreas
extent
worth
note
bioactiv
pegyl
determin
examin
pegyl
site
residu
aminoterminu
higher
activ
compar
residu
ly
ly
poor
pharmacokinet
determin
conjug
peg
mass
previou
studi
aminotermin
pegyl
kda
linear
peg
exhibit
biolog
activ
halflif
h
allow
viral
diseas
treat
fewer
dose
longer
dose
interv
use
human
fc
fusion
protein
also
demonstr
simpl
effect
method
prolong
serum
halflif
studi
show
compar
express
yeast
specif
activ
iumg
lower
activ
iumg
express
chines
hamster
ovari
cell
furthermor
termin
halflif
higher
exhibit
better
pharmacokinet
characterist
perhap
becom
new
altern
antivir
drug
treatment
chronic
viral
infect
sever
studi
also
reveal
glycosyl
essenti
effect
activ
ifn
glycosyl
potent
bovin
viral
diarrhea
viru
yellow
fever
viru
west
nile
viru
possibl
explan
potenc
glycosyl
could
induc
activ
sterol
regulatori
element
bind
transcript
factor
activ
enhanc
bind
protein
site
interferon
consensu
sequenc
bind
protein
erythroid
kruppellik
factor
gene
homeot
gene
forkhead
drosophila
nuclear
factor
mous
forkhead
lung
protein
interferon
conserv
sequencebind
protein
lymphocyteenrich
dna
bind
protein
lyf
induc
glycosyl
also
exhibit
good
clinic
applic
previou
studi
show
glycosyl
ribavirin
rbv
synergist
effect
term
antivir
activ
hepat
c
viru
hcv
infect
patient
similarli
synergi
antivir
effect
glycosyl
rbv
bovin
viral
diarrhea
viru
also
obtain
interestingli
antagon
cytotox
effect
rbv
glycosyl
observ
thu
combin
glycosyl
rbv
appear
favor
synergi
antivir
activ
antagon
cytotox
effect
rbv
increas
evid
suggest
may
associ
nonspecif
immun
respons
base
increas
surviv
time
presenc
acutephas
protein
serum
amyloida
creactiv
protein
phagocyt
activ
whole
blood
cell
macrophag
natur
killer
cell
activ
reduc
concurr
viral
excret
gener
increas
number
isg
mx
protein
zap
could
enhanc
pathogen
detect
innat
immun
signal
indic
elicit
immun
respons
cell
treat
express
upregul
dosedepend
timedepend
manner
recent
studi
leal
et
al
show
interleukin
il
product
affect
consider
felin
immunodefici
viru
fiv
infect
cat
treat
recombin
felin
subcutan
oral
protocol
specif
plasma
level
decreas
provir
load
increas
fivcat
treat
subcutan
mrna
express
decreas
oral
group
howev
therapi
affect
viremia
express
cytokin
tumor
necrosi
thu
appear
involv
innat
immun
could
inhibit
viral
replic
exert
antivir
activ
ifn
demonstr
antiprolif
effect
result
induc
cellcycl
arrest
apoptosi
independ
pathway
similar
also
inhibit
cell
prolifer
dosedepend
manner
howev
exhibit
higher
antiprolif
activ
elev
concentr
also
exhibit
antitumor
activ
vitro
cellspecif
manner
felin
mammari
carcinoma
among
common
felin
tumor
repres
import
caus
mortal
use
treat
felin
canin
mammari
carcinoma
cell
deriv
put
tumoriniti
cell
exhibit
dosedepend
speciesspecif
target
cellspecif
action
addit
effect
observ
convent
anticanc
drug
mitoxantron
doxorubicin
vincristin
thu
may
use
therapeut
agent
felin
canin
mammari
carcinoma
evid
show
gene
transfer
would
allow
one
take
advantag
benefici
effect
type
ifn
without
undesir
side
effect
instanc
gene
lipofect
produc
equal
even
superior
effect
high
dose
exogen
appli
protein
recent
studi
conduct
villaverd
et
al
demonstr
felin
gene
lipofect
exhibit
equal
higher
cytotox
effect
kind
effect
due
induct
reactiv
oxygen
speci
gener
mitochondri
membran
potenti
disrupt
calcium
uptak
indic
lipofect
altern
approach
treat
sensit
resist
phenotyp
equal
superior
outcom
fewer
advers
effect
recombin
therapi
similarli
inject
gene
encod
interferon
via
tail
vein
mice
bear
liver
tumor
via
liposom
gene
deliveri
also
significantli
decreas
tumor
weight
interestingli
effect
greater
tumor
inhibit
plasmid
contain
human
thymosin
alpha
dna
ladder
hallmark
cell
undergo
apoptosi
observ
tumor
cell
treat
interestingli
antitumor
mechan
involv
increas
express
plasmidliposom
complex
togeth
exert
greater
potenc
inhibit
growth
tumor
cell
either
compound
alon
antivir
immunomodulatori
antiprolifer
antitumor
activ
explor
treatment
option
diseas
viral
infect
human
anim
display
antitumor
effect
sever
model
human
cancer
vivo
addit
also
use
diagnos
diseas
produc
silkworm
larva
use
baculoviru
vector
includ
sequenc
immunomodul
regist
mani
countri
eg
japan
australia
new
zealand
mexico
treat
canin
parvoviru
felin
leukemia
viru
felv
fiv
infect
http
emeaeuropaeu
despit
fact
licens
treat
viral
infect
exhibit
efficaci
use
treat
viral
infect
bovin
enteroviru
infecti
bovin
rhinotrach
viru
bovin
viral
diarrhea
viru
vesicular
stomat
viru
pseudorabi
viru
european
bat
lyssaviru
influenza
viru
felin
caliciviru
fcv
felin
licens
protocol
consist
three
therapeut
cycl
five
daili
subcutan
inject
mukg
begin
respect
day
howev
widespread
use
limit
protocol
rel
expens
timeconsum
altern
subcutan
topic
protocol
oral
intralesion
administr
suggest
interestingli
advers
effect
found
cat
treat
follow
mucos
administr
subcutan
administr
accompani
mild
advers
effect
eg
fever
lethargi
vomit
diarrhea
trial
thu
could
becom
option
treatment
veterinari
clinic
practic
hcv
major
public
health
problem
approxim
million
infect
worldwid
mani
hcvinfect
individu
elimin
viru
persist
infect
hcv
caus
chronic
liver
diseas
includ
cirrhosi
hepatocellular
carcinoma
combin
rbv
standard
care
chronic
hcv
infect
howev
mani
deleteri
side
effect
furthermor
hcv
chronic
carrier
suitabl
therapi
new
antivir
approach
need
studi
show
equal
effect
inhibit
hcv
replic
compar
interestingli
combin
exhibit
primarili
antagonist
interact
addit
studi
show
activ
nonglycosyl
compar
glycosyl
potent
repress
hcv
rna
replicon
thu
use
prospect
antivir
candid
treatment
hcv
infect
addit
potenti
therapi
hcv
could
also
use
diagnos
human
diseas
monogen
diseas
caus
mutat
autoimmun
regul
air
gene
current
mani
autoantibodi
includ
target
aromat
acid
decarboxylas
tyrosin
hydroxylas
nacht
leucinerich
repeat
protein
tryptophan
hydroxylas
found
patient
studi
shown
antibodi
highli
preval
patient
mutat
air
allel
even
though
presenc
antibodi
preced
clinic
symptom
develop
autoantibodi
therefor
antibodi
becom
essenti
diagnost
tool
numer
avail
assay
immunoassay
radioligand
bind
assay
antivir
neutral
assay
design
detect
antibodi
howev
drawback
includ
lack
sensit
use
radioisotop
requir
facil
grow
viral
cultur
well
timeconsum
novel
diagnos
method
also
develop
zhang
et
al
report
ipa
base
ilabel
show
higher
sensit
antityp
ifn
antibodi
patient
examin
similar
studi
zhang
et
al
patient
also
investig
studi
ofted
et
al
patient
also
posit
antibodi
determin
ipa
base
slabel
also
exhibit
greater
correl
antityp
ifn
antibodi
result
suggest
spectrum
antityp
ifn
antibodi
test
antibodi
suitabl
patient
suspect
recent
larosa
et
al
develop
novel
highli
sensit
specif
assay
measur
antibodi
found
ilabel
assay
result
discrep
sampl
respect
agre
air
gene
result
regard
measur
antibodi
studi
patient
assay
seem
better
perform
diseasespecif
reliabl
precis
assay
make
possibl
assess
patient
patient
suspect
prior
air
gene
analysi
fcv
member
calicivirida
famili
import
common
pathogen
cat
character
clinic
sign
rang
mild
sever
oral
ulcer
upper
respiratori
tract
diseas
sever
fatal
system
diseas
unfortun
still
directact
antivir
drug
treatment
fcv
previou
studi
demonstr
posit
therapeut
effect
fcvinfect
cat
experi
trial
combin
antivir
therapi
becom
common
practic
recent
research
reveal
combin
treatment
mefloquin
result
addit
effect
reduct
half
maxim
inhibitori
concentr
anoth
studi
conduct
lee
et
al
show
rel
express
mx
zap
mrna
crandellrees
felin
kidney
cell
upregul
significantli
fcvinfect
cat
interestingli
cat
pretreat
korean
red
ginseng
krg
extract
ginsenosid
express
gene
higher
group
treat
fcv
alon
desir
find
combin
krg
extract
ginsenosid
effect
treat
fcvinfect
cat
similar
structur
characterist
genom
structur
fcv
could
repres
human
noroviru
surrog
thu
therapi
could
also
use
treat
human
noroviru
infect
doublestrand
dna
viru
replic
nucleu
host
cell
produc
intranuclear
inclus
bodi
one
foremost
caus
felin
upper
respiratori
tract
diseas
demonstr
dosedepend
inhibitori
effect
replic
vitro
sever
studi
show
conflict
result
biolog
activ
two
virus
cat
instanc
cat
suffer
fcvassoci
felin
upper
respiratori
tract
diseas
treat
intraven
dose
mukg
three
time
per
day
everi
day
improv
clinic
sign
detect
within
day
control
group
use
studi
anoth
studi
cat
ocular
kerat
treat
five
time
per
day
dose
muml
although
signific
improv
ocular
sign
observ
week
treatment
control
group
includ
use
placebo
control
group
effect
cat
pretreat
challeng
investig
unexpectedli
benefici
effect
observ
cat
ballin
et
al
report
similar
find
found
compar
control
group
treat
placebo
cat
treat
exhibit
improv
clinic
sign
acut
viral
felin
upper
respiratori
tract
diseas
despit
lower
fcv
copi
number
cat
receiv
studi
need
verifi
therapeut
effect
vivo
felv
endogen
retroviru
belong
genu
gammaretroviru
famili
retrovirida
caus
varieti
degen
immunosuppress
disord
sever
anorexia
cachexia
progress
weak
studi
indic
affect
felv
cycl
posttranscript
level
howev
alter
protein
synthesi
treatment
lower
revers
transcriptas
activ
use
evalu
amount
infecti
viral
particl
dosedepend
manner
felvinfect
cell
furthermor
accord
half
maxim
inhibitori
concentr
potent
inhibit
revers
transcriptas
activ
addit
studi
show
decreas
viabil
felvinfect
cell
increas
apoptosi
mortal
infect
cell
fiv
felin
lentiviru
first
describ
mani
studi
focus
complex
genom
immunopathogen
featur
similar
human
immunodefici
viru
furthermor
fiv
coinfect
found
occur
felvinfect
cat
previou
studi
show
significantli
decreas
clinic
score
rate
mortal
improv
abnorm
hematolog
paramet
red
blood
cell
count
pack
cell
volum
white
blood
cell
count
virusinfect
cat
studi
demonstr
signific
therapeut
effect
clinic
sign
evid
also
show
effect
immun
modul
fivcat
could
obtain
treat
oral
previou
studi
fivinfect
cat
oral
administ
dose
mucat
gain
weight
although
dramat
chang
obtain
regard
viral
load
ratio
howev
studi
assess
clinic
benefit
recent
oral
protocol
also
use
administ
natur
fivinfect
cat
initi
clinic
score
obtain
similar
obtain
use
licens
subcutan
protocol
interestingli
similar
use
licens
protocol
also
induc
signific
clinic
improv
cat
treat
oral
despit
viral
excret
signific
variat
acutephas
protein
result
suggest
oral
administr
effect
altern
therapi
fivinfect
cat
fcg
multifactori
diseas
infecti
viral
diseas
fiv
felv
also
trigger
fcg
induc
immun
suppress
dysregul
studi
show
oral
treatment
benefici
therapi
fcg
studi
conduct
hennet
et
al
found
oral
protocol
correl
obviou
clinic
improv
fcg
lesion
caudal
stomat
alveolarbucc
mucos
furthermor
differ
corticosteroid
better
pain
relief
obtain
treatment
recent
two
clinic
case
show
use
oral
also
effect
type
ii
diabet
cat
fcg
studi
clinic
improv
oral
lesion
concurr
reduct
requir
insulin
dose
posit
relationship
therapi
agre
hennet
work
show
overal
relief
pain
refractori
case
fcg
parvoviru
small
nonenvelop
singlestrand
dna
viru
infect
human
carnivor
hostspecif
manner
canin
parvoviru
cpv
felin
panleukopenia
viru
mink
enter
viru
share
approxim
homolog
nucleotid
amino
acid
sequenc
sever
therapi
use
treat
cpv
infect
howev
mani
drawback
report
suggest
signific
therapeut
effect
cpvinfect
dog
instanc
improv
parvovir
clinic
sign
pyrexia
vomit
anorexia
diarrhea
reduc
sever
parvovir
enter
mortal
cpv
infect
studi
kuwabara
et
al
show
continu
immunoenhanc
treatment
whole
blood
cell
count
dog
might
essenti
improv
sever
clinic
symptom
caus
cpv
infect
cpxv
belong
orthopoxviru
genu
frequent
found
domest
cat
case
report
endem
northern
europ
western
area
former
soviet
union
howev
antivir
drug
licens
cure
cat
cpxv
infect
recent
studi
conduct
mcinerney
et
al
show
treatment
certain
protect
effect
cat
infect
cpxv
although
two
four
cat
studi
die
nevertheless
may
potenti
use
treat
cpxvassoci
pneumonia
dermat
cat
note
addit
research
need
confirm
fibrosarcoma
common
diseas
cat
account
skin
tumor
speci
current
success
treatment
fibrosarcoma
report
cat
although
treatment
felin
fibrosarcoma
demonstr
safe
well
toler
easili
perform
studi
hampel
et
al
reveal
increas
express
major
histocompat
molecul
felin
fibrosarcoma
cell
eosinophilia
neutropenia
weight
loss
remark
reduc
treatment
howev
placebocontrol
trial
need
cad
common
allerg
skin
diseas
therapeut
protocol
report
allergenspecif
immunotherapi
use
topic
oral
glucocorticoid
calcineurin
inhibitor
essenti
fatti
acid
supplement
bath
howev
none
highli
efficaci
sever
sideeffect
observ
occasion
fortun
studi
show
treat
dog
cad
subcutan
administ
compar
efficaci
orallyadminist
cyclosporin
later
studi
oral
ifn
therapi
show
higher
efficaci
subcutan
treatment
term
canin
atop
dermat
extent
sever
index
total
score
although
improv
pruritu
qualiti
life
score
signific
howev
studi
serum
antibodi
detect
dog
fip
common
immunemedi
diseas
trigger
infect
felin
coronaviru
previou
studi
show
benefici
therapi
fipinfect
cat
howev
studi
use
fewer
cat
per
group
includ
control
group
furthermor
effect
reliabl
confirm
fip
instanc
studi
cat
suspect
fip
cat
treat
ukg
felin
everi
day
remiss
follow
inject
everi
week
four
cat
live
longer
year
subsequ
studi
conduct
ritz
et
al
control
group
use
signific
differ
surviv
time
cat
treat
placebo
although
treatment
result
significantli
lower
lymphocyt
count
interestingli
one
cat
surviv
month
group
result
suggest
could
also
certain
therapeut
effect
fipinfect
cat
ifn
demonstr
similar
level
biolog
activ
limit
toxic
side
effect
thu
may
use
altern
antivir
agent
although
regist
treat
cpv
felv
fiv
infect
show
compar
efficaci
use
treat
viral
infect
diseas
howev
safeti
eg
toxic
side
effect
use
high
dose
investig
extens
addit
antivir
activ
fatal
infecti
diseas
also
need
evalu
laboratori
confirm
antivir
activ
foot
mouth
diseas
viru
publish
yet
although
antivir
activ
viral
infect
remain
investig
studi
import
evalu
efficaci
anim
model
ultim
human
trial
